NASDAQ:NMRA | Free Cash Flow | Neumora Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2022-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$46.4M
2025-12-31-$47.96M
2025-03-31-$59.45M
2024-12-31-$50.34M
2024-03-31-$42.96M
2023-12-31-$51.44M$44,000.00-$51.49M
2023-03-31-$33.04M$36,000.00-$33.08M
2022-12-31-$30.37M$23,000.00-$30.39M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$206.44M
2024-12-31-$182.94M
2023-12-31-$163.28M$117,000.00-$163.4M
2022-12-31-$114.9M$511,000.00-$115.41M